DDInter1840 DDInter8
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 2011, respectively. It is used to treat metastatic castration-resistant prostate cancer and hormone-sensitive high-risk metastatic prostate cancer.[L40968, L40193, L47740, L47745] As abiraterone has poor oral bioavailability and is susceptible to hydrolysis by esterases, abiraterone acetate was developed as an orally bioavailable prodrug with enhanced stability and absorption.[A3811, A260835]
Trabectedin {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Abiraterone
Trabectedin {u} (Compound) causes {v} (Side Effect) Hypokalaemia
Hypokalaemia {u} (Side Effect) is caused by {v} (Compound) Abiraterone
Trabectedin {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Nelfinavir
Nelfinavir {u} may cause a minor interaction that can limit clinical effects when taken with {v} Abiraterone
Trabectedin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Testosterone
Testosterone {u} (Compound) resembles {v} (Compound) Abiraterone
Trabectedin {u} (Compound) causes {v} (Side Effect) Hypokalaemia
Hypokalaemia {u} (Side Effect) is caused by {v} (Compound) Testosterone
Testosterone {u} (Compound) resembles {v} (Compound) Abiraterone
Trabectedin {u} (Compound) causes {v} (Side Effect) Blood alkaline phosphatase increased
Blood alkaline phosphatase increased {u} (Side Effect) is caused by {v} (Compound) Delavirdine
Delavirdine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Abiraterone
Trabectedin {u} (Compound) causes {v} (Side Effect) Hepatotoxicity
Hepatotoxicity {u} (Side Effect) is caused by {v} (Compound) Duloxetine
Duloxetine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Abiraterone
Trabectedin {u} (Compound) causes {v} (Side Effect) Body temperature increased
Body temperature increased {u} (Side Effect) is caused by {v} (Compound) Boceprevir
Boceprevir {u} may cause a minor interaction that can limit clinical effects when taken with {v} Abiraterone
Trabectedin {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Abiraterone
Trabectedin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is associated with {v} (Disease) prostate cancer
prostate cancer {u} (Disease) is treated by {v} (Compound) Abiraterone
Trabectedin (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Abiraterone (Compound)
Trabectedin (Compound) causes Hypokalaemia (Side Effect) and Hypokalaemia (Side Effect) is caused by Abiraterone (Compound)
Trabectedin (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Nelfinavir (Compound) and Nelfinavir may cause a minor interaction that can limit clinical effects when taken with Abiraterone
Trabectedin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Testosterone (Compound) and Testosterone (Compound) resembles Abiraterone (Compound)
Trabectedin (Compound) causes Hypokalaemia (Side Effect) and Hypokalaemia (Side Effect) is caused by Testosterone (Compound) and Testosterone (Compound) resembles Abiraterone (Compound)
Trabectedin (Compound) causes Blood alkaline phosphatase increased (Side Effect) and Blood alkaline phosphatase increased (Side Effect) is caused by Delavirdine (Compound) and Delavirdine may cause a minor interaction that can limit clinical effects when taken with Abiraterone
Trabectedin (Compound) causes Hepatotoxicity (Side Effect) and Hepatotoxicity (Side Effect) is caused by Duloxetine (Compound) and Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone
Trabectedin (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Boceprevir (Compound) and Boceprevir may cause a minor interaction that can limit clinical effects when taken with Abiraterone
Trabectedin (Compound) binds SRC (Gene) and SRC (Gene) is bound by Dasatinib (Compound) and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone
Trabectedin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is associated with prostate cancer (Disease) and prostate cancer (Disease) is treated by Abiraterone (Compound)